Clinical Trials Using Anti-Endoglin Chimeric Monoclonal Antibody TRC105
Clinical trials are research studies that involve people. The clinical trials on this list are studying Anti-Endoglin Chimeric Monoclonal Antibody TRC105. All trials on the list are supported by NCI.
NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.
Letrozole, Everolimus, and Anti-Endoglin Chimeric Monoclonal Antibody TRC105 in Treating Postmenopausal Patients with Hormone-Receptor Positive or HER2 Negative Breast Cancer That Can Be Removed by Surgery
This phase I / II trial studies the side effects and best dose of anti-endoglin chimeric monoclonal antibody TRC105 and everolimus when given together with letrozole in treating patients with hormone-receptor positive or human epidermal growth factor receptor 2 (HER2) negative breast cancer that has not spread or spread from where it started to nearby tissue and can be removed by surgery. Anti-endoglin chimeric monoclonal antibody TRC105 may stop the growth of tumor cells by blocking the growth of new blood vessels necessary for tumor growth. Drugs used in chemotherapy, such as everolimus, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Drugs, such as letrozole, may lessen the amount of estrogen made by the body. Giving anti-endoglin chimeric monoclonal antibody TRC105, everolimus and letrozole may work better in treating patients with breast cancer.
Location: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama